S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NYSE:NGVT

Ingevity (NGVT) Stock Price, News & Analysis

$48.95
+1.55 (+3.27%)
(As of 04:32 PM ET)
Today's Range
$47.58
$49.04
50-Day Range
$40.04
$47.96
52-Week Range
$36.66
$89.92
Volume
274,652 shs
Average Volume
243,793 shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Ingevity MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.4% Downside
$48.75 Price Target
Short Interest
Healthy
2.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Ingevity in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
52.36%
From $3.82 to $5.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Basic Materials Sector

131st out of 171 stocks

Chemicals & Allied Products Industry

14th out of 17 stocks

NGVT stock logo

About Ingevity Stock (NYSE:NGVT)

Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment comprises of pavement technologies, industrial specialties, and engineered polymers. It manufactures products derived from crude tall oil and lignin extracted from the kraft pulping process, as well as caprolactone monomers and derivatives derived from cyclohexanone and hydrogen peroxide. This segment's products are used in various applications comprising warm mix paving, pavement preservation, pavement reconstruction and recycling, road striping, oil well service additives, oil production, and downstream applications; and adhesives, agrochemical dispersants, lubricants, printing inks, industrial intermediates and oilfield, coatings, resins, elastomers, bioplastics, and medical devices. The company was founded in 1964 and is headquartered in North Charleston, South Carolina.

NGVT Stock Price History

NGVT Stock News Headlines

Ingevity price target raised by $7 at Wells Fargo, here's why
Ingevity: Hold Rating Amidst Transition and Macroeconomic Uncertainties
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Ingevity (NYSE:NGVT) Shares Gap Up After Strong Earnings
Strange Money Secret Used by the Ultra-Wealthy
If you have any money in a U.S. bank account, you need to see this today –  it could help shield your savings through the turbulence ahead.
Ingevity (NGVT) Q4 Earnings and Revenues Beat Estimates
Ingevity earnings: here's what Wall Street expects
Ingevity's Earnings Outlook
Ingevity (NGVT) to Release Earnings on Wednesday
Ingevity Corp.
NGVT: Raising target price to $40.00
Ingevity (NGVT) Declined on Lowering Full-Year Guidance
See More Headlines
Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/23/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
N/A
Previous Symbol
NASDAQ:NGVT
Employees
2,050
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.00
High Stock Price Target
$55.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+5.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$211.60 million
Pretax Margin
9.60%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$9.58 per share
Book Value
$18.68 per share

Miscellaneous

Free Float
35,945,000
Market Cap
$1.72 billion
Optionable
Optionable
Beta
1.88
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John C. Fortson (Age 57)
    President, CEO & Director
    Comp: $2.57M
  • Ms. Mary Dean Hall (Age 66)
    Executive VP & CFO
    Comp: $1.14M
  • Ms. Stacy Lancaster Cozad (Age 53)
    Executive VP, General Counsel & Secretary
    Comp: $1.05M
  • Mr. Stuart Edward Woodcock Jr.Mr. Stuart Edward Woodcock Jr. (Age 58)
    Executive VP & President of Performance Materials
    Comp: $960.98k
  • Mr. Richard White (Age 61)
    Senior VP & President of Performance Chemicals
    Comp: $854.88k
  • Mr. Phillip John Platt (Age 43)
    VP, Chief Accounting Officer & Business Transformation Lead
  • John E. Nypaver Jr.
    VP of Investor Relations & Treasurer
  • Caroline Monahan
    Director of Communications
  • Ms. Christine Stunyo (Age 45)
    Senior VP & Chief Human Resources Officer
  • Mr. Steve Hulme (Age 55)
    Senior VP & President of Advanced Polymer Technologies














NGVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Ingevity stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings
or view top-rated stocks.

What is Ingevity's stock price target for 2024?

4 Wall Street research analysts have issued 12-month price objectives for Ingevity's stock. Their NGVT share price targets range from $43.00 to $53.00. On average, they predict the company's stock price to reach $48.75 in the next year. This suggests that the stock has a possible downside of 0.4%.
View analysts price targets for NGVT
or view top-rated stocks among Wall Street analysts.

How have NGVT shares performed in 2024?

Ingevity's stock was trading at $47.22 on January 1st, 2024. Since then, NGVT shares have increased by 3.7% and is now trading at $48.95.
View the best growth stocks for 2024 here
.

Are investors shorting Ingevity?

Ingevity saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 755,800 shares, a decline of 8.6% from the January 15th total of 827,100 shares. Based on an average trading volume of 261,500 shares, the short-interest ratio is presently 2.9 days. Currently, 2.1% of the shares of the stock are short sold.
View Ingevity's Short Interest
.

When is Ingevity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NGVT earnings forecast
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) posted its quarterly earnings results on Wednesday, February, 21st. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.34. The firm had revenue of $371.70 million for the quarter, compared to analysts' expectations of $336.74 million. Ingevity had a positive trailing twelve-month return on equity of 20.11% and a negative net margin of 0.32%. The firm's revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.57 earnings per share.

What ETFs hold Ingevity's stock?
What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.4 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.33%), Victory Capital Management Inc. (5.12%), LSV Asset Management (3.53%), Brown Advisory Inc. (2.19%), Southernsun Asset Management LLC (2.05%) and Dimensional Fund Advisors LP (2.05%). Insiders that own company stock include Erik Spencer Ripple, Phillip John Platt, Richard Allen White Jr and Stuart Edward Jr Woodcock.
View institutional ownership trends
.

How do I buy shares of Ingevity?

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NGVT) was last updated on 2/23/2024 by MarketBeat.com Staff

From Our Partners